Clearmind Medicine eyes FDA breakthrough status for lead alcohol use disorder candidate
Clearmind Medicine (NASDAQ:CMND) announced on Monday, April 27, 2026, that it is evaluating its lead drug candidate, CMND-100 (MEAI), for a potential FDA Breakthrough Therapy Designation (BTD).










